These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35649164)

  • 1. Structure-Based Discovery of Novel NH
    Jin X; Zhao LM; Wang S; Huang WJ; Zhang YX; Pannecouque C; De Clercq E; Chen FE
    J Med Chem; 2022 Jun; 65(12):8478-8492. PubMed ID: 35649164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
    Jin K; Yin H; De Clercq E; Pannecouque C; Meng G; Chen F
    Eur J Med Chem; 2018 Feb; 145():726-734. PubMed ID: 29353724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus.
    Zhou Z; Liu T; Wu G; Kang D; Fu Z; Wang Z; De Clercq E; Pannecouque C; Zhan P; Liu X
    Org Biomol Chem; 2019 Mar; 17(12):3202-3217. PubMed ID: 30839042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment Hopping-Based Design of Novel Biphenyl-DAPY Derivatives as Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Improved Anti-Resistance Efficacy.
    Sang YL; Pannecouque C; De Clercq E; Wang S; Chen FE
    J Med Chem; 2023 Apr; 66(7):4755-4767. PubMed ID: 36996328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Sang Y; Pannecouque C; De Clercq E; Zhuang C; Chen F
    Bioorg Chem; 2020 Mar; 96():103595. PubMed ID: 32006797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
    Jin X; Piao HR; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Eur J Med Chem; 2021 Dec; 226():113868. PubMed ID: 34583311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
    Ding L; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    J Med Chem; 2021 Jul; 64(14):10297-10311. PubMed ID: 34197708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
    Chen X; Ding L; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Eur J Med Chem; 2020 Sep; 202():112549. PubMed ID: 32712537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel".
    Zhou Z; Liu T; Kang D; Huo Z; Wu G; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Org Biomol Chem; 2018 Feb; 16(6):1014-1028. PubMed ID: 29349445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains.
    Sang Y; Han S; Han S; Pannecouque C; De Clercq E; Zhuang C; Chen F
    Bioorg Chem; 2019 Aug; 89():102974. PubMed ID: 31102693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and SAR of naphthyl-substituted Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Liang YH; Feng XQ; Zeng ZS; Chen FE; Balzarini J; Pannecouque C; De Clercq E
    ChemMedChem; 2009 Sep; 4(9):1537-45. PubMed ID: 19591191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of novel S-N
    Ling X; Hao QQ; Huang WJ; Pannecouque C; De Clercq E; Wang S; Chen FE
    Eur J Med Chem; 2023 Feb; 247():115042. PubMed ID: 36577220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Sang Y; Han S; Pannecouque C; De Clercq E; Zhuang C; Chen F
    Eur J Med Chem; 2019 Nov; 182():111603. PubMed ID: 31421633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and anti-human immunodeficiency virus activity of substituted ( o,o-difluorophenyl)-linked-pyrimidines as potent non-nucleoside reverse transcriptase inhibitors.
    Čechová L; Dejmek M; Baszczyňski O; Šaman D; Gao L; Hu E; Stepan G; Jansa P; Janeba Z; Šimon P
    Antivir Chem Chemother; 2019; 27():2040206619826265. PubMed ID: 30788976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
    Ludovici DW; De Corte BL; Kukla MJ; Ye H; Ho CY; Lichtenstein MA; Kavash RW; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Das K; Arnold E; Janssen PA
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2235-9. PubMed ID: 11527705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
    Ding L; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    J Med Chem; 2021 Apr; 64(8):5067-5081. PubMed ID: 33851529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
    Jiang X; Huang B; Olotu FA; Li J; Kang D; Wang Z; De Clercq E; Soliman MES; Pannecouque C; Liu X; Zhan P
    Eur J Med Chem; 2021 Mar; 213():113051. PubMed ID: 33279288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.
    Huang B; Chen W; Zhao T; Li Z; Jiang X; Ginex T; Vílchez D; Luque FJ; Kang D; Gao P; Zhang J; Tian Y; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    J Med Chem; 2019 Feb; 62(4):2083-2098. PubMed ID: 30721060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Yan ZH; Wu HQ; Chen WX; Wu Y; Piao HR; He QQ; Chen FE; De Clercq E; Pannecouque C
    Bioorg Med Chem; 2014 Jun; 22(12):3220-6. PubMed ID: 24794751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.